

# Assertive outreach for people with schizophrenia in Germany

<b>Submission date</b>	<b>Recruitment status</b>	<input type="checkbox"/> Prospectively registered
01/12/2011	No longer recruiting	<input type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
27/01/2012	Completed	<input checked="" type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
12/04/2017	Mental and Behavioural Disorders	

## Plain English summary of protocol

### Background and study aims

The German mental health system often lacks the ability to provide integrated and intensified outpatient care for people with severe mental illness. Assertive Outreach (AO), an approach for an intensive, community-based health care delivery, could help to overcome some of the deficits. A model of AO treatment in which office-based psychiatrists collaborate with ambulatory nursing services to provide a complex model of intensive homecare is currently being used in rural areas of Lower Saxony, Germany. The aim of this study is to investigate the effectiveness and efficiency of this model for adult patients suffering from schizophrenia, a severe long-term mental health condition.

### Who can participate?

Patients aged 18 or older with schizophrenia

### What does the study involve?

Patients receiving AO are compared to patients who are not eligible for AO because this treatment model is not reimbursed by their health insurance (they receive treatment as usual). The observation period for each patient spans over 12 months with assessments every 3 months for healthcare use and every 6 months for all other parameters (psychopathology, level of functioning, patient satisfaction with care and healthcare costs).

### What are the possible benefits and risks of participating?

It is hoped that patients receiving AO require fewer days of hospital treatment than patients receiving treatment as usual. The findings from the study will be of great help for the further development of mental healthcare in Germany.

### Where is the study run from?

Leuphana University Lueneburg (Germany)

### When is the study starting and how long is it expected to run for?

May 2011 to March 2012.

## Who is funding the study?

The study is funded through European Funds for Regional Development and through the Federal State of Lower Saxony within the framework of the Innovation-Incubator at Leuphana University Lueneburg (Germany)

## Who is the main contact?

Jörn Moock

joern.moock@inkubator.leuphana.de

# Contact information

## Type(s)

Scientific

## Contact name

Prof Wulf Roessler

## Contact details

Volgershall 1

Lueneburg

Germany

21339

+49 (0)413 1677 5581

roessler@dgsp.uzh.ch

# Additional identifiers

## Protocol serial number

DRKS00003351

# Study information

## Scientific Title

Comparing assertive outreach with standard care for people with schizophrenia in Germany: health care utilization, psychopathology and level of functioning after 12 months

## Study objectives

Assertive outreach (AO) is superior to standard care for people with schizophrenia. Patients receiving assertive outreach use significantly fewer days of inpatient treatment than patients receiving standard care. In addition, AO leads to better clinical and functional outcomes, to greater patient satisfaction with care and lower health care costs compared to standard care.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Ethics Commission & Medical Association in Lower Saxony (Ethikkommission bei der Ärztekammer Niedersachsen), 14/03/2011, ref: Bo/03/2011

## Study design

Multi-centred naturalistic quasi-randomised controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Treatment

## **Health condition(s) or problem(s) studied**

Schizophrenia

## **Interventions**

1. Assertive Outreach (with home care and case management provided by a mental health nurse, a 24-hour, seven days a week available crisis service, psychoeducation, an evidence informed treatment guideline and a strong collaboration between the psychiatrist and ambulatory nursing service)
2. Treatment as usual

## **Intervention Type**

Other

## **Phase**

Not Applicable

## **Primary outcome(s)**

Number of days spent in inpatient psychiatric care measured with the German version of the Client Socio-demographic and Service Receipt Inventory (CSSRI, interview with the patient) at baseline (t0) and every three month within 1 year (t1-t4).

## **Key secondary outcome(s)**

1. Psychosocial functioning, measured with the WHO-Disability Assessment Scale II (patient rating) and the Global Assessment of Functioning (physician rating) at baseline (t0) and after 6 month and 12 month (t2 and t4)
2. Psychopathology, measured with the Brief Psychiatric Rating Scale (physician rating) and a 2-item-version of the Alcohol Use and Drug Use Scale (patient rating) at t0, t2 and t4
3. Life satisfaction, measured with single item (11-point scale, patient rating) at t0, t2 and t4
4. Patient satisfaction with care, measured with the short version of the Patient Assessment of Chronic Care (patient rating) at t0, t2 and t4
5. Direct and indirect costs, measured with the CSSRI (interview) at t0-t4

## **Completion date**

31/03/2013

## **Eligibility**

### **Key inclusion criteria**

Adult patients (18 years or older) with a clinical diagnosis of schizophrenia (F20) and moderate or severe impairments in the level of functioning rated by the physician using the global assessment of function scale (Global Assessment of Functioning (GAF)  $\leq 60$ )

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Patients with medium or severe cognitive impairments or organic mental disorder
2. Patients with insufficient language ability
3. Individuals who are unwilling or unable to give informed consent to the study participation
4. Patients who refuse Assertive Outreach

**Date of first enrolment**

03/05/2011

**Date of final enrolment**

31/03/2013

## Locations

**Countries of recruitment**

Germany

**Study participating centre**

Volgershall 1

Lueneburg

Germany

21339

## Sponsor information

**Organisation**

European Fund for Regional Development (Germany)

# Funder(s)

## Funder type

Government

## Funder Name

European Funds for Regional Development (Germany)

## Funder Name

Federal State of Lower Saxony (Germany)

## Funder Name

Innovation-Incubator, Leuphana University Lueneburg (Germany)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	15/02/2013		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes